Opko Health Inc (OPK)

$1.33 -0.01 (-0.75%)
Market Cap 1.06B
Revenue (ttm) 713.14M
Net Income (ttm) -53.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7.46%
Debt to Equity Ratio 0.26
Volume 1,864,700
Avg Vol 3,264,554
Day's Range N/A - N/A
Shares Out 793.05M
Stochastic %K 14%
Beta 1.34
Analysts Strong Sell
Price Target $3.09

Company Profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 305 575 4100
Address:
4400 Biscayne Boulevard, Miami, United States
Mike18181
Mike18181 Jul. 15 at 8:30 PM
$OPK Add up 2007 to 2025 at approximatly a loss yearly of (4) quarters. AT AROUND -150 million to -200 milion of accumulated deficits total annually.. *On start up use losses and get rid of accumlated deficits. The company uses tax loss carry forwards to lower there tax liability quarter over quarter. Opko could not manage to see this. So, they went to Toxic Financing at low common stock prices. Results. FACTS - WIPED CLEAN shareholder book value plus dillution. Not Ok... press on and look what you got. A board that has to listen to Frosts Control. All bad ideas. Kept loading expenditure and No budget. 450 million in cash did not even move the needle. Why ? Too many shares, astranomical accumulated deficits , novearing, no rev increase. Fiduciary resposibility Where ? Have Frost let a new CEO lead the team. Question ? If retained earnings cant carry Opko, what happens when the 450m is eating up in 18 months. Float more notes. You dont Finance operations at 1.34.
1 · Reply
magadog
magadog Jul. 15 at 6:26 PM
$OPK The best way for this heap to unlock value is, sell for scrap and stop paying people for doing nothing
0 · Reply
Bigdog98
Bigdog98 Jul. 15 at 2:32 PM
$OPK frosty's last rodeo looks like a failure, looking like he's going to have to book a loss on this one, sad
0 · Reply
Brasil07
Brasil07 Jul. 15 at 1:39 PM
$OPK terrible Indeed...
0 · Reply
Mike18181
Mike18181 Jul. 15 at 10:45 AM
$OPK After careful number crunching and data I found , My accounting as a Former CFO has produced this on Opko. A book value after all dillution pollution . 1.13 to 1.20 per share. All items were entered and its a low number because of the -2.26 billion accumulated deficits. This number is horrible. So your common stock equity is Wiped out. Mist CEO would have bern out long b ago. But tge control kept this going. Its A Shame !!
0 · Reply
myuri
myuri Jul. 15 at 8:38 AM
$OPK no news?👀
0 · Reply
Mike18181
Mike18181 Jul. 15 at 4:25 AM
$OPK 450miliion in cash might be used for Corporate purposes, Executive bonuses and 13D holders of 5% or more for lavish trips, catering, and dividends payout. Honest shareholder get to Penny Flip since 2007. Also the crumbs on floor are shareholder benefits for Loyalty
0 · Reply
Mike18181
Mike18181 Jul. 14 at 8:03 PM
$OPK Phil Frost dartboard is available at the shareholder online gift shop located in the Opk HQ lobby
0 · Reply
Mike18181
Mike18181 Jul. 14 at 5:02 PM
$OPK Opko on recommended list, " recommend you to have your head examined after yiu buy..
1 · Reply
Brasil07
Brasil07 Jul. 14 at 2:28 PM
$OPK Seem that market wait a Frost departed....and than Opko go to the Moon...
1 · Reply
Latest News on OPK
NextPlat Issues Interim CEO Update Shareholder Letter

Jun 30, 2025, 8:01 AM EDT - 15 days ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

Jun 25, 2025, 11:00 AM EDT - 20 days ago

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

OPKO Health to Participate in Two Upcoming Investor Conferences

May 15, 2025, 8:00 AM EDT - 2 months ago

OPKO Health to Participate in Two Upcoming Investor Conferences

OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 7:52 PM EDT - 2 months ago

OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Apr 4, 2025, 8:00 AM EDT - 3 months ago

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

OPKO and Entera partner to develop obesity pill

Mar 17, 2025, 8:57 AM EDT - 4 months ago

OPKO and Entera partner to develop obesity pill

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Mar 11, 2025, 7:00 AM EDT - 4 months ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

LH

OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:12 PM EST - 4 months ago

OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

Feb 27, 2025, 4:10 PM EST - 4 months ago

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 11:45 AM EST - 6 months ago

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

Nov 18, 2024, 8:00 AM EST - 8 months ago

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NXPL

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

Nov 14, 2024, 6:00 AM EST - 8 months ago

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

BABA NXPL

OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 8:30 PM EST - 8 months ago

OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Oct 7, 2024, 8:00 AM EDT - 10 months ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

Oct 7, 2024, 8:00 AM EDT - 10 months ago

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

NXPL

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Sep 16, 2024, 7:30 AM EDT - 10 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

LH

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 7, 2024, 4:06 PM EDT - 1 year ago

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

Jul 17, 2024, 4:14 PM EDT - 1 year ago

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

OPKO Health to Participate in the Jefferies Global Healthcare Conference

May 31, 2024, 10:48 AM EDT - 1 year ago

OPKO Health to Participate in the Jefferies Global Healthcare Conference

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript

May 7, 2024, 8:03 PM EDT - 1 year ago

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

May 3, 2024, 8:00 AM EDT - 1 year ago

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

LH

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Mar 5, 2024, 8:52 AM EST - 1 year ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 8:08 PM EST - 1 year ago

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Feb 27, 2024, 4:05 PM EST - 1 year ago

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Feb 22, 2024, 4:05 PM EST - 1 year ago

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

Jan 9, 2024, 4:05 PM EST - 1 year ago

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Jan 4, 2024, 11:31 PM EST - 1 year ago

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Jan 3, 2024, 5:05 PM EST - 1 year ago

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Nov 28, 2023, 7:00 AM EST - 1 year ago

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Nov 7, 2023, 6:45 AM EST - 1 year ago

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

SOPH

OPKO Health, Inc. (OPK) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 7:32 PM EST - 1 year ago

OPKO Health, Inc. (OPK) Q3 2023 Earnings Call Transcript

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 1 year ago

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Nov 2, 2023, 10:00 AM EDT - 1 year ago

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 31, 2023, 8:00 AM EDT - 1 year ago

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Oct 25, 2023, 4:25 PM EDT - 1 year ago

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

OPKO Health: FDA Approval To Save The Company

Oct 20, 2023, 1:30 PM EDT - 1 year ago

OPKO Health: FDA Approval To Save The Company

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Sep 28, 2023, 4:08 PM EDT - 1 year ago

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript

Aug 4, 2023, 12:17 AM EDT - 2 years ago

OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript

OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings

Jul 31, 2023, 2:19 PM EDT - 2 years ago

OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

Jul 25, 2023, 4:05 PM EDT - 2 years ago

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

Jun 28, 2023, 6:45 AM EDT - 2 years ago

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

PFE

OPKO Health's Future After Merck Deal: Bright Or Uncertain

May 11, 2023, 12:29 PM EDT - 2 years ago

OPKO Health's Future After Merck Deal: Bright Or Uncertain

MRK

OPKO Health, Inc. (OPK) Q1 2023 Earnings Call Transcript

May 3, 2023, 8:42 PM EDT - 2 years ago

OPKO Health, Inc. (OPK) Q1 2023 Earnings Call Transcript

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

May 3, 2023, 4:05 PM EDT - 2 years ago

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

Strong Small-Cap Insider Buys: Q1 2023

Apr 26, 2023, 12:15 AM EDT - 2 years ago

Strong Small-Cap Insider Buys: Q1 2023

AAT ABBV BY CCB CCO CMP ENVX

OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023

Apr 25, 2023, 4:05 PM EDT - 2 years ago

OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023

OPKO Health, Inc. (OPK) Q4 2022 Earnings Call Transcript

Feb 23, 2023, 8:56 PM EST - 2 years ago

OPKO Health, Inc. (OPK) Q4 2022 Earnings Call Transcript

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

Feb 23, 2023, 4:05 PM EST - 2 years ago

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

Mike18181
Mike18181 Jul. 15 at 8:30 PM
$OPK Add up 2007 to 2025 at approximatly a loss yearly of (4) quarters. AT AROUND -150 million to -200 milion of accumulated deficits total annually.. *On start up use losses and get rid of accumlated deficits. The company uses tax loss carry forwards to lower there tax liability quarter over quarter. Opko could not manage to see this. So, they went to Toxic Financing at low common stock prices. Results. FACTS - WIPED CLEAN shareholder book value plus dillution. Not Ok... press on and look what you got. A board that has to listen to Frosts Control. All bad ideas. Kept loading expenditure and No budget. 450 million in cash did not even move the needle. Why ? Too many shares, astranomical accumulated deficits , novearing, no rev increase. Fiduciary resposibility Where ? Have Frost let a new CEO lead the team. Question ? If retained earnings cant carry Opko, what happens when the 450m is eating up in 18 months. Float more notes. You dont Finance operations at 1.34.
1 · Reply
magadog
magadog Jul. 15 at 6:26 PM
$OPK The best way for this heap to unlock value is, sell for scrap and stop paying people for doing nothing
0 · Reply
Bigdog98
Bigdog98 Jul. 15 at 2:32 PM
$OPK frosty's last rodeo looks like a failure, looking like he's going to have to book a loss on this one, sad
0 · Reply
Brasil07
Brasil07 Jul. 15 at 1:39 PM
$OPK terrible Indeed...
0 · Reply
Mike18181
Mike18181 Jul. 15 at 10:45 AM
$OPK After careful number crunching and data I found , My accounting as a Former CFO has produced this on Opko. A book value after all dillution pollution . 1.13 to 1.20 per share. All items were entered and its a low number because of the -2.26 billion accumulated deficits. This number is horrible. So your common stock equity is Wiped out. Mist CEO would have bern out long b ago. But tge control kept this going. Its A Shame !!
0 · Reply
myuri
myuri Jul. 15 at 8:38 AM
$OPK no news?👀
0 · Reply
Mike18181
Mike18181 Jul. 15 at 4:25 AM
$OPK 450miliion in cash might be used for Corporate purposes, Executive bonuses and 13D holders of 5% or more for lavish trips, catering, and dividends payout. Honest shareholder get to Penny Flip since 2007. Also the crumbs on floor are shareholder benefits for Loyalty
0 · Reply
Mike18181
Mike18181 Jul. 14 at 8:03 PM
$OPK Phil Frost dartboard is available at the shareholder online gift shop located in the Opk HQ lobby
0 · Reply
Mike18181
Mike18181 Jul. 14 at 5:02 PM
$OPK Opko on recommended list, " recommend you to have your head examined after yiu buy..
1 · Reply
Brasil07
Brasil07 Jul. 14 at 2:28 PM
$OPK Seem that market wait a Frost departed....and than Opko go to the Moon...
1 · Reply
Bigdog98
Bigdog98 Jul. 14 at 1:19 PM
$OPK always riding that promise of tomorrow, never delivering 2day... B%LLSH*T
0 · Reply
Bigdog98
Bigdog98 Jul. 14 at 1:14 PM
$OPK announce buyback and dilute the hell out of us...thats next level F'KERY
0 · Reply
Fixaleg
Fixaleg Jul. 14 at 1:05 PM
$OPK company is the ultimate pump job going all the way back to 4/share in 2007 as they have NEVER had a profitable year of operation. All their products have declining revenues and are antiquated in the market. Folks like to hype the "insider buying" but in reality it is just Frost trying to stimulate investors to have confidence in the operations, but look at the chart as it is 25% of the value from 2007 and experienced only two periods of short lived upside movement that was primarily based on hype and pump. They have had products cancelled, disappear, clinical failures and the list goes on with only 3-4 failing products and lots of promises. Buyer Beware and do homework, not listen to pumpers! Never been short and had invested over the years and glad for profits and moved on due to no results by company #DO_NOT_INVEST_IN_OPK
1 · Reply
SleepingDragon4
SleepingDragon4 Jul. 14 at 12:35 PM
$OPK they did fantastic at their conference yesterday I’m buying !!!
1 · Reply
Bigdog98
Bigdog98 Jul. 14 at 11:59 AM
$OPK imo frosty has created the perfect storm for failure, the stock cant stand this much abuse from mgt, a sale only way out, and have to think that might be disappointing as well, total failure on mgt's part as far as i'm concerned
1 · Reply
tymtested
tymtested Jul. 13 at 10:01 PM
$OPK over 7000 attendees at ENDO 2025! Hope opko makes a good impression!
0 · Reply
tymtested
tymtested Jul. 13 at 6:14 PM
$OPK TODAY! MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA.
0 · Reply
tymtested
tymtested Jul. 13 at 1:39 AM
$OPK OPKO and Entera expect to file an Investigational New Drug application with the U.S. Food and Drug Administration later this year for both oral OPK-88006 tablet and a weekly injectable variant of the same molecule, which OPKO intends to develop independently. Phase 1 clinical studies are being planned.
1 · Reply
Biotechguy21
Biotechguy21 Jul. 12 at 11:50 PM
$OPK does frosty use an auto pen like sleep joe did?
0 · Reply
Biotechguy21
Biotechguy21 Jul. 12 at 11:48 PM
$OPK checking in. CEO in jail yet?
0 · Reply
Mike18181
Mike18181 Jul. 12 at 6:42 PM
$OPK OPKO executives your Competence is the best ive ever seen.
0 · Reply
tymtested
tymtested Jul. 12 at 12:42 PM
$OPK Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome Poster Viewing Date & Time: September 13, 2025, 3:30 - 4:00 p.m. local time & Welcome Reception Poster Topic: Poster Session 1 - Liver and gastrointestinal tract Location of Display: Forum Hall Foyer 3 The oral GLP-2 tablet program combines a proprietary long acting GLP-2 agonist developed by OPKO with Entera’s proprietary N-Tab™ technology for patients suffering from short bowel syndrome and additional disorders involving gastrointestinal mucosal inflammation and nutrient malabsorption. Currently, the only approved GLP-2 agonist, which is marketed under the brand GATTEX® (teduglutide), requires daily subcutaneous injections.
2 · Reply